Percheron Therapeutics Limited (PER, formerly Antisense Therapeutics Limited), is a publicly listed biotechnology company developing and commercializing pharmaceuticals for rare diseases with unmet medical need. The company involves in development of ATL1102, an antisense inhibitor of the CD49d receptor, which is currently the subject of an ongoing international Phase IIb trial for non-ambulant subjects with Duchenne Muscular Dystrophy.